Fairmount Funds Management LLC
Spyre Therapeutics, Inc. · Director
Fairmount Funds Management LLC is listed in filings as Director at Spyre Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 23, 2026, including sale activity and purchase activity. Recent filings connect the profile to Spyre Therapeutics, Inc. (SYRE), Zenas BioPharma, Inc. (ZBIO), Viridian Therapeutics, Inc. (VRDN), and Oruka Therapeutics, Inc. (ORKA). The current snapshot covers public activity from Jun 12, 2024 to Jun 23, 2026. Reported amounts are shown as $399.7M to $6.0M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $6M316.2k shares | BuyOct 7, 2025 | $19.00 | $29.50 | |
| $3M150k shares | BuyMar 31, 2026 | $20.00 | $29.50 | |
| $30M1.6M shares | BuySep 13, 2024 | $18.75 | $18.03 | |
| $10M454.5k shares | BuyOct 23, 2025 | $22.00 | $18.03 | |
| $20M1.2M shares | BuyMay 11, 2026 | $17.00 | $18.03 | |
| $25M2.8M shares | BuyJul 10, 2025 | $9.00 | $37.94 | |
| $127M3.5M shares | SellJan 22, 2026 | $36.40 | $37.94 | |
| $243M7M shares | SellMar 31, 2026 | $34.66 | $37.94 | |
| $134M1.8M shares | SellJan 22, 2026 | $76.30 | $134.08 |